WebFeb 27, 2024 · Financial Highlights. Cash position: As of December 31, 2024, the Company held cash and cash equivalents and investment securities of $392.8 million, compared to $556.3 million as of December 31 ... WebMay 24, 2024 · CSL Behring is a global leader in the plasma protein biotherapeutics industry. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Organization. ... Australian Financial Review — CSL says no patient data was stolen by ex-staffer .
Full Year Results 2024 - CSL
WebMar 24, 2024 · As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. WebMar 16, 2024 · The estimated total pay for a Director at CSL Behring is $339,691 per year. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. The estimated base pay is $174,443 per year. The estimated additional pay is $165,248 per year. the year 1676
CSL Behring - Funding, Financials, Valuation & Investors
WebUnderstanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. WebInformation on stock, financials, earnings, subsidiaries, investors, and executives for CSL. Use the PitchBook Platform to explore the full profile. ... CSL Behring either uses plasma-derived pro. Biotechnology. Parkville, Australia. 30,000 As of 2024 00.000. 000000000 00.000. 000000. WebCSL Behring. Feb 2024 - Present6 years 1 month. King of Prussia, PA. • Responsible for the consolidation and financial reporting for 145 global entities, providing consolidated financial ... safety task force image